Oncotarget

Research Papers:

Effectiveness of capecitabine with or without docetaxel therapy for the treatment of patients with advanced urothelial carcinoma: a single-institution experience

Cong Xue, Xin An, Ye Cao, Tanhuan Chen, Wei Yang, Yingfei Deng, Hui Han, Xiaoyu Teng, Fangjian Zhou and Yanxia Shi _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:63722-63729. https://doi.org/10.18632/oncotarget.11641

Metrics: PDF 634 views  |   HTML 1313 views  |   ?  


Abstract

Cong Xue1,*, Xin An1,*, Ye Cao2, Tanhuan Chen1, Wei Yang 1, Yingfei Deng1, Hui Han3, Xiaoyu Teng1, Fangjian Zhou3, Yanxia Shi1

1Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, People’s Republic of China

2Department of GCP, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, People’s Republic of China

3Department of Urology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, People’s Republic of China

*These authors contributed equally to this work

Correspondence to:

Yanxia Shi, email: shiyx@sysucc.org.cn

Fangjian Zhou, email: zhoufj@sysucc.org.cn

Keywords: capecitabine, docetaxel, second-line, chemotherapy, urothelial cancer

Received: December 14, 2015     Accepted: July 29, 2016     Published: August 26, 2016

ABSTRACT

Purpose: The purpose of this study was to evaluate the effectiveness and toxicity of capecitabine (C) chemotherapy regimen with or without (w/o) docetaxel (D) in patients with advanced urothelial carcinoma (UC).

Results: Clinical benefit rate were similar in two arms (C arm vs DC arm: 38.9% vs 45.5%, p = 0.411). There were two cases achieved partial response in DC arm. In C arm, the median PFS was 3.0 months (95% CI 2.5–3.5 months) and median OS was 11.3 months (95% CI 8.6–14.1 months). In DC arm, the median PFS was 2.2 months (95% CI 1.7–2.7 months) and median OS was 18 months (95% CI 6.8–29.9 months). Adverse events were mostly acceptable, including myelosuppession, hand-foot syndrome and mucositis. Anemia and leukopenia was found more in the DC arm than in the C arm.

Materials and Methods: This is a one-center, observational, retrospective study. From April 2009 to March 2015, a total of 29 patients with metastatic UC were included in the study. Survivals, response rates and toxicities were collected retrospectively.

Conclusions: The result showed the activity and toxicity of C w/o D. As DC treatment did not reveal better outcome, C or D single-agent might be an option in platinum-failed patients with advanced urothelial carcinoma. Further clinical trials are warranted.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 11641